American Association for Cancer Research
crc-22-0265-s01.pptx (42.11 kB)

Table S1 from Reprogramming of tumor reactive Tumor Infiltrating Lymphocytes to human induced Pluripotent Stem Cells

Download (42.11 kB)
posted on 2023-05-11, 14:20 authored by SM Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L Good, Rigel J Kishton, Biman C. Paria, Zhiya Yu, Marta Bosch-Marce, Nicole M Bedanova, Chengyu Liu, Michael J Kruhlak, Nicholas P Restifo, Raul Vizcardo

Table S1 indicating TIL-iPSCs were established from T cells of low frequency along with major tumor neoantigen specific T cells from patient 3784



Tumor-infiltrating lymphocytes (TIL) that can recognize and kill tumor cells have curative potential in subsets of patients treated with adoptive cell transfer (ACT). However, lack of TIL therapeutic efficacy in many patients may be due in large part to a paucity of tumor-reactive T cells in TIL and the exhausted and terminally differentiated status of those tumor-reactive T cells. We sought to reprogram exhausted TIL that possess T cell receptors (TCR) specific for tumor antigens into induced pluripotent stem cells (iPSCs) to rejuvenate them for more potent ACT. We first attempted to reprogram tumor neoantigen-specific TIL by αCD3 Ab pre-stimulation which resulted in failure of establishing tumor-reactive TIL-iPSCs, instead, T-iPSCs from bystander T cells were established. To selectively activate and enrich tumor-reactive T cells from the heterogenous TIL population, CD8+ PD-1+ 4-1BB+ TIL population were isolated after co-culture with autologous tumor cells, followed by direct reprogramming into iPSCs. TCR sequencing analysis of the resulting iPSC clones revealed that reprogrammed TIL-iPSCs encoded TCRs that were identical to the pre-identified tumor-reactive TCRs found in minimally cultured TIL. Moreover, reprogrammed TIL-iPSCs contained rare tumor antigen-specific TCRs, which were not detectable by TCR sequencing of the starting cell population. Thus, reprogramming of PD-1+ 4-1BB+ TIL after co-culture with autologous tumor cells selectively generates tumor antigen-specific TIL-iPSCs, and is a distinctive method to enrich and identify tumor antigen-specific TCRs of low frequency from TIL.